American Century Companies Inc. Has $628,000 Position in Oric Pharmaceuticals, Inc. $ORIC

American Century Companies Inc. boosted its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 4.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,628 shares of the company’s stock after buying an additional 4,766 shares during the period. American Century Companies Inc. owned about 0.16% of Oric Pharmaceuticals worth $628,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Oric Pharmaceuticals by 34.0% in the fourth quarter. Bank of America Corp DE now owns 112,520 shares of the company’s stock valued at $908,000 after buying an additional 28,570 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Oric Pharmaceuticals by 16.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company’s stock worth $5,788,000 after acquiring an additional 103,237 shares during the last quarter. Vivo Capital LLC boosted its position in Oric Pharmaceuticals by 62.8% during the 1st quarter. Vivo Capital LLC now owns 2,080,450 shares of the company’s stock worth $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Sphera Funds Management LTD. grew its stake in shares of Oric Pharmaceuticals by 112.8% in the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company’s stock valued at $2,205,000 after buying an additional 144,817 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of Oric Pharmaceuticals by 14.3% in the fourth quarter. Two Sigma Advisers LP now owns 66,500 shares of the company’s stock valued at $537,000 after buying an additional 8,300 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Insider Buying and Selling at Oric Pharmaceuticals

In other news, Director Angie You purchased 26,597 shares of the business’s stock in a transaction dated Friday, June 20th. The stock was bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the purchase, the director owned 26,597 shares of the company’s stock, valued at $249,745.83. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dominic Piscitelli sold 32,466 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the transaction, the chief financial officer owned 68,317 shares of the company’s stock, valued at $717,328.50. The trade was a 32.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,400 shares of company stock valued at $390,263 in the last quarter. 6.82% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ORIC shares. Guggenheim started coverage on shares of Oric Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, August 14th. HC Wainwright decreased their target price on Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. Finally, LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a “buy” rating and a $15.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.63.

Oric Pharmaceuticals Price Performance

Shares of NASDAQ:ORIC opened at $10.77 on Friday. The company has a market capitalization of $1.05 billion, a PE ratio of -5.70 and a beta of 1.63. The business has a fifty day moving average price of $10.39 and a two-hundred day moving average price of $8.06. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). Sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.